Co dnes víme o přínosu snižování glykémie pro kardiovaskulární systém?

Souhrn

V posledních letech nabývá na intenzitě diskuse, která se týká způsobu léčby a terapeutických cílů u diabetu 2. typu. Poprvé od ukončení studie UKPDS (United Kingdom Prospective Diabetes Study) a studie DIS (Diabetes Interventions Study) se uskutečnilo hned několik velkých klinických studií, které mají odpovědět na otázku, zda a do jaké míry může úprava zvýšených hodnot glykémie snížit kardiovaskulární riziko. Jde o vysoce aktuální a závažnou otázku, vzhledem k alarmujícím počtům úmrtí z kardiovaskulárních příčin, k nimž dochází u pacientů s diabetem 2. typu. Není sporu, že u těchto pacientů s vysokým rizikem musí být léčba zaměřena jak na metabolické, tak na kardiovaskulární faktory.

Resümee

Die Diskussion um Therapie und Therapieziele beim Typ-2-Diabetes ist in der jüngsten Vergangenheit neu entbrannt: erstmals seit UKPDS (United Kingdom Prospective Diabetes Study) und der Diabetesinterventionsstudie (DIS) haben gleich mehrere große Untersuchungen Stellung zur umstrittenen Frage genommen, ob und in welchem Ausmaß die Absenkung erhöhter Blutzuckerwerte das Risiko für Herz-Kreislauf-Ereignisse reduziert. Eine hochaktuelle und zentrale Frage, wenn man an die alarmierenden Zahlen kardiovaskulärer Todesfälle unter Typ-2-Diabetikern denkt. Die Notwendigkeit einer doppelten Fokussierung auf metabolische und kardiovaskuläre Komponenten in dieser Hochrisikogruppe ist unstrittig.

_________________________________________________________________________________________________________________

Plnou verzi najdete v časopisu Medicína po promoci číslo 4/2010 

---

Prof. Dr. med. M. Hanefeld; Dr. med. M. Schönauer; Dr. med. T. Forst Prof. Dr. med. M. Hanefeld, Zentrum für Klinische Studien, GWT-TUD GmbH, Dresden. Dr. med. M. Schönauer, Gemeinschaftspraxis Dr. Schönauer, Leipzig. Dr. med. T. Forst, Institut für klinische Forschung und Entwicklung GmbH, Mainz. Adresa pro korespondenci: Prof. Dr. med. Markolf Hanefeld, Zentrum für Klinische Studien, GWT-TUD GmbH, Fiedlerstrasse 34, 01307 Dresden, BRD.
E-mail: hanefeld@gwtonline-zks.de Dtsch Med Wochenschr 2010;135:301-307. Copyright c 2010 Georg Thieme Verlag KG Stuttgart - New York


---

LITERATURA

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2459.

2. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.

3. Al Majali K, Cooper MB, Staels B, et al. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modifi cation by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006;49:527-537.

4. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000;23:1605-1611.

5. Berhanu P, Kipnes MS, Khan MA, et al. effects of pioglitazone on lipid and lipoprotein profi les in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006;3:39-44.

6. Campia U, Matuskey LA, Panza JA. Peroxisome proliferatoractivated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006;113:867-875.

7. Ceriello A, Johns D, Widel M, et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005;28:266-272.

8. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-1104.

9. Daikeler R, Erdmann E, Forst T, et al. Wissenschaftlich Evidenz in der ärztlichen Praxis: 10 Thesen zur Wirksamkeit und Verträglichkeit einer Therapie mit Glitazonen. Diabetes, Stoff wechsel, Herz 2006;6:94-99.

10. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-2464.

11. Derosa G, Cicero AF, Dangelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005; 28:917-924.

12. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5-13.

13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study: a randomised controlled trial. Lancet 2005;366:1279-1289.

14. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.

15. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780.

16. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by diff erent mechanisms. Diabetes Care 2008;31:121-127.

17. Füllert S, Schneider F, Haak E, et al. effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebocontrolled study. J Clin Endocrinol Metab 2002;87:5503-5506.

18. Goldberg RB, Kendall DM, Deeg MA, at al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554.

19. Hanefeld M, Brunetti P, Schernthaner GH, et al. QUARTET one-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-147.

20. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583.

21. Hanefeld M, Schmechel H, Schwanebeck U, Lindner J. Predictors of coronary heart disease and death in NIDDM: the Diabetes Intervention Study experience. Diabetologia 1997; 40 (Suppl 2): S123-124.

22. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997;14 (Suppl 3):S6-11.

23. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.

24. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.

25. Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. Br Med J 2009; 339:b2942.

26. Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004;27:41-46.

27. Miyazaki Y, Mahankali A, Matsuda M, et al. effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.

28. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.

29. Nissen SE, Wolski K. effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.

30. Pavo I, Jermendy G, Varkonyi TT, et al. effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:1637-1645.

31. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-1931.

32. Pop-Busui R, Lombardero M, Lavis V, et al. Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). Am J Cardiol 2009;104:52-58.

33. Ray KK, Seshasai SR, Wijesuriya S, et al. effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772.

34. Roden M, Laakso M, Johns D et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with type 2 diabetes mellitus. Diabet Med 2005;22:1101-1106.

35. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26:2493-2499.

36. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-6076.

37. Schneider CA, Ferrannini E, Defronzo R, et al. effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008;19:182-187.

38. Szapary PO, Bloedon LT, Samaha FF, et al. effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:182-188.

39. Tan MH, Glazer NB, Johns D, et al. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004;20:723-728.

40. Tan MH, Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profi les in patients with Type 2 diabetes. Diabet Med 2004;21:859-866.

41. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-873.

42. Winkler K, Konrad T, Füllert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003;26:2588-2594.

43. Zietemann V, Storz P, Freytag A, et al. HTA Bericht zur Effektivität, zur Anwendungssicherheit und zur gesundheitsökonomischen Bewertung von Pioglitazon und Rosiglitazon bei der Behandlung des Typ 2 Diabetes mellitus. IGES Institut GmbH, 2008Berichts-Nr: HTAi006; http://gripsdb. himdi.de/de/hta/hta_berichte/hta231_bericht_de.pdf

Zdroj: Medicína po promoci